Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic ...

Retrieved on: 2024-04-06 17:22:59

Tags for this article:

Muscarinic agonists

Schizophrenia

Atypical antipsychotics

Muscarinic antagonists

Dopamine antagonists

Xanomeline/trospium

Management of schizophrenia

Click the tags to see associated articles and topics

Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic .... View article details on HISWAI: https://finance.yahoo.com/news/bristol-myers-squibb-presents-pooled-171500095.html

Excerpt

... Data from the EMERGENT Program Evaluating KarXT ... analysis included 718 patients who received at least one dose of KarXT, with 134 patients having ...

Article found on: finance.yahoo.com

View Original Article